Seven years after the U.S. stock market was de-listed, Synth Pharmaceuticals listed on the Hong Kong Stock Exchange

more than three months after the company filed for an IPO on the Hong Kong Stock Exchange, Synsheng Pharmaceuticals was officially listed on the Hong Kong Stock Exchange yesterday (October 27). According to the latest offering announcement on October 23rd, the IPO will sell 260,569,000 shares worldwide, with Hong Kong and international offerings each accounting for half of the shares, at HK$13.70 each.Of course, despite being 590 times oversubscribed, Sonic Pharmaceuticals was unable to escape the break. The opening price of HK$11, down 20 per cent from the offering price, is now down 25 per cent.In fact, this is the second IPO by Synth Pharmaceuticals since it was de-marketed. In 2007, as China's first bio-chemical pharmaceutical company to land on the New York Stock Exchange, Synth Pharmaceuticals set a new IPO record for an Asian chemical and biopharmaceutical company. However, as a result of the financial crisis, Synsheng Pharmaceuticals' share price has suffered frequent setbacks, and after the failure of its acquisition of Yanshen Bio, the deeply undervalued drug company finally decided to withdraw from the U.S. stock market.According to public information, Sonic Pharmaceuticals is a pharmaceutical company driven by innovation and research and development, and is on a promising and fast-growing track in the pharmaceutical market, focusing on cancer diseases (including cell therapy), central nervous system diseases, autoimmune diseases, and more. These three therapeutic areas account for 24.7% of china's pharmaceutical market in terms of drug sales revenue in 2019.Thanks to this strategy and diversified product layout, Synsheng Pharmaceuticals' total revenue has steadily increased in the past three years, and its net profit has risen exponentially, ranking among the "Top 10 Chinese Innovative Pharmaceutical Companies" and "Top 100 Pharmaceutical Industry in China" for many years.Although the core revenue of Synth Pharmaceuticals still relies on traditional products, nearly 50 new drugs in the future will inevitably bring new changes to China's pharmaceutical industry. Of course, these new drugs are in the early stages of clinical development, there is no short-term income-generating possibility, so the performance of A basip injections, "first must be new", KN035 or will directly determine the future of the first sound pharmaceutical industry.From an investor's point of view, the listing of Synth Pharmaceuticals has attracted much attention. Seven cornerstone investors, including Gaoxuan Capital and Obo Capital, subscribed for about $190 million in shares, which accounted for about 41.25 percent of the total IPO offering. At present, the initial public offering of Synth Pharmaceuticals has ended, small and medium-sized investors subscribe enthusiastically, the offering price is set at the high end of the IPO range. (Biological exploration)